Phoenix Children’s Hospital Research
Institute (PCRI) Website Clinical Trial Listing
** Please complete and return to Shy Walker at
swalker@phoenixchildrens.com
Study Title:
ACCL0933- A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent
Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia
(AML)
Study Purpose (2-3 sentences in laymen terms):
In this study, researchers want to find out if using a newer antifungal drug called caspofungin (also
called Cancidas) will be better than the current standard antifungal drug fluconazole at preventing
invasive fungal infections when given to people with AML after receiving chemotherapy treatment.
Study Summary (1 paragraph in laymen terms):
Prevention of Invasive Fungal Infections (IFI) is important for successful treatment of patients with AML. The
current standard antifungal medication used in the prevention of IFI in patients with AML is Fluconazole. The
goal of this study is to compare Fluconazole and Caspofungin, a newer antifungal medication, to determine
which is better for the prevention of IFI. To learn if one antifungal treatment is better, each child is assigned
randomly to one of the treatments: the Fluconazole Arm or the Caspofungin Arm. If for any reason the
treatment plan is found to be not the best for your child, the plan will be changed
Basic Eligibility Criteria:
• Age: 3 months-30 years old
• Diagnosis: Newly diagnosed, relapsed or secondary acute myelocytic leukemia (AML).
Please consult with your doctor to determine whether your child may participate in this study.
Study Location(s):
Phoenix Children’s Hospital and other institutions that are members of the Children’s Oncology
Group
Study Contact(s):
Jessica Boklan, MD
Dianne Peterson, Research Coordinator (dpeterson@phoenixchildrens.com)